Impact of Nanoparticulate Drug Delivery System of Herbal Drug in Control of Diabetes Mellitus

Based on the invitro drug release profile of Gymnemic acid nanoparticles formulations (GNP1-GNP5) formulation GNP3 is selected as the best preparation in which the particle size was 195 nm[1]. Since from ancient times the naturopathic treatment for diseases has been explored widely and in advance momentum in the present situation, and has several pharmacological significance. [...]from the DSC study, it was found no interaction between Gymnemic acid and other excipients used in the formulation. Based on the study the material of drug-excipient has no characteristic color change and there is no significant changes in the chemical evaluation this indicates that the drug and ingredients added are compatible with each other.the results are given below in the table 3 * As a result, the zetapotential rate for GNP3 was obtained maximum of 19.6 mV. * The particle size has no changes [24]. * Particle size and entrapment efficiency of the Gymnemic acid nanoparticles(GNP1- GNP5) were greater than before with increasing Chitosan concentration. * This is because of elevated quantity of availability of Chitosan to encapsulate the drug, in the lead increase the Chitosan concentration, number of layers coated the drug was improved, thus results in increased particle size and entrapment efficiency[25]. * Further increase in the Chitosan concentration (GNP4-GNP5), has no more augment in the entrapment efficiency because the accessibility of the drug to be included is small which is not enough for further encapsulation of drug by Chitosan. [...]it can be concluded that the newly formulated controlled release nanoparticulate drug delivery[35] systems of Gymnemic acid may be ideal and effective in the treatment of diabetes mellitus by allowing the drug to release continuously for 24 hrs. 5.